Gastroenterology clinics of North America

• 

  Año 2014, Vol. 43, Número 3. Texto Completo Ejemplar. Dedicado a: Biologics in Inflammatory Bowel Disease

  • Immunology of Inflammatory Bowel Disease and Molecular Targets for Biologics

    Maneesh Dave, Konstantinos Papadakis, William A. Faubion

    • Resumen
    • Texto completo

    págs. 405-424

    

  • Who Should Receive Biologic Therapy for IBD?: The Rationale for the Application of a Personalized Approach

    Jennifer Jones, Juan Nicolás Peña Sánchez

    • Resumen
    • Texto completo

    págs. 425-440

    

  • Anti–Tumor Necrosis Factor-α Monotherapy Versus Combination Therapy with an Immunomodulator in IBD

    Parambir S. Dulai, Corey A. Siegel, Laurent Peyrin-Biroulet

    • Resumen
    • Texto completo

    págs. 441-456

    

  • Update on Anti-Tumor Necrosis Factor Agents in Crohn Disease

    Siddharth Singh, Darrell S. Pardi

    • Resumen
    • Texto completo

    págs. 457-478

    

  • An Update on Anti-TNF Agents in Ulcerative Colitis

    Mark A. Samaan, Preet Bagi, Niels Vande Casteele, Geert R. D'Haens, Barrett G. Levesque

    • Resumen
    • Texto completo

    págs. 479-494

    

  • The Use of Biologic Agents in Pregnancy and Breastfeeding

    Sara Horst, Sunanda Kane

    • Resumen
    • Texto completo

    págs. 495-508

    

  • Risk of Infections with Biological Agents

    Uri Kopylov, Waqqas Afif

    • Resumen
    • Texto completo

    págs. 509-524

    

  • The Risk of Malignancy Associated with the Use of Biological Agents in Patients with Inflammatory Bowel Disease

    Parambir S. Dulai, Corey A. Siegel

    • Resumen
    • Texto completo

    págs. 525-541

    

  • Miscellaneous Adverse Events with Biologic Agents (Excludes Infection and Malignancy)

    Joseph D. Feuerstein, Adam S. Cheifetz

    • Resumen
    • Texto completo

    págs. 543-563

    

  • Pharmacokinetics of Biologics and the Role of Therapeutic Monitoring

    Kirk Lin, Uma Mahadevan

    • Resumen
    • Texto completo

    págs. 565-579

    

  • Lymphocyte Homing Antagonists in the Treatment of Inflammatory Bowel Diseases

    Brigid S. Boland, William J. Sandborn, John T. Chang

    • Resumen
    • Texto completo

    págs. 581-601

    

  • Update on Ustekinumab for the Treatment of Crohn's Disease

    Yvette Leung, Remo Panaccione

    • Resumen
    • Texto completo

    págs. 619-630